Navigation Links
Beyond the Failed Beta Amyloid Hypothesis -- Alzheimer's Experts to Discuss Need for New Medicines with Alternative Mechanisms of Action in Pre-CTAD Conference Webinar
Date:11/29/2016

BOULDER, Colo., Nov. 29, 2016 /PRNewswire/ -- Several leading Alzheimer's disease experts will participate in a webinar hosted by Accera, Inc. at 11 a.m. EST on December 6 in advance of the 9th Annual International Conference on Clinical Trials for Alzheimer's Disease (CTAD). The program will include discussions on the role of metabolism in Alzheimer's disease and therapeutic targets that address deficient glucose metabolism observed in Alzheimer's disease patients.

"Following the recent failure of another therapy targeting the amyloid hypothesis, now more than ever we need to focus on alternative mechanisms to address Alzheimer's disease," said Michael Gold, M.D., Accera's senior medical advisor and the moderator of the webinar. "As the Alzheimer's community prepares to gather for CTAD, we want to provide perspectives from researchers leading the way to address the fundamental metabolic defect in Alzheimer's patients."

Dr. Gold will moderate a discussion following presentations by:

Dr. Swerdlow will present information about the history of the metabolic hypothesis and the role of mitochondrial defects in Alzheimer's disease. He is the Director of the University of Kansas Alzheimer's Disease Center and the KUMC Neurodegenerative Disorders Program. Dr. Swerdlow is a Professor in the Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and Molecular Biology at the University of Kansas School of Medicine. After receiving his undergraduate and doctor of medicine degrees from New York University, he trained as a neurologist and cognitive disorders subspecialist at the University of Virginia. Dr. Swerdlow sees patients at the University of Kansas Memory Disorders Clinic and is a laboratory-based neuroscientist who is internationally known for his work on mitochondrial dysfunction in neurodegenerative diseases.

Dr. Trushina will present information on emerging mitochondria-targeted therapeutics. Her laboratory is focused on mitochondrial dysfunction caused by environmental toxins, chemotherapy drugs and genetic factors in multiple neurodegenerative disorders, including Huntington's disease and Alzheimer's disease, aging, and chemotherapy-induced peripheral neuropathy. Her research interests involve identification of the molecular mechanisms involved in the inhibition of mitochondrial dynamics and function in neurons. Dr. Trushina's current projects include the development of a panel of the biomarkers associated with mitochondrial dysfunction involved in neurodegeneration and testing novel mitochondria-targeted therapeutic approaches that could potentially reverse neurodegeneration and aging. Dr. Trushina has a Ph.D. from Saratov State University in Russia and conducted postdoctoral studies at the Mayo Clinic College of Medicine. Dr. Trushina's research has been funded by the Mayo Clinic Alzheimer's Disease Research Center, the American Health Assistance Foundation, the Alzheimer Drug Discovery Foundation and the National Institutes of Health.

Accera's lead product candidate, AC-1204, addresses the issue of deficient glucose metabolism in Alzheimer's disease by inducing a mild form of ketosis by generating ketones for use in neurons. These ketones have the potential to restore the supply of energy, improving neuronal metabolism and in turn cognition and function in patients with mild to moderate Alzheimer's disease. AC-1204 is currently being evaluated in a double-blind, placebo-controlled Phase 3 study called NOURISH AD. Results from this study are expected in the coming months.

Webinar Information

Participants can register in advance and access the webinar by clicking the following link: https://www.webcaster4.com/Webcast/Page/1588/18619. Participants are encouraged to log on within 15 minutes prior to the beginning of the webinar. Following the event, a replay will be available at the same link and on the Accera website.

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Boulder, Colo., that is developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.

Follow Accera on Twitter at twitter.com/accerainc.

Accera Media Contacts:                                                     

Russo Partners LLC

Todd Davenport, Ph.D.
(212) 845-4235                                                          
todd.davenport@russopartnersllc.com

Rich Allan                                                                  
(646) 942-5588
rich.allan@russopartnersllc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beyond-the-failed-beta-amyloid-hypothesis----alzheimers-experts-to-discuss-need-for-new-medicines-with-alternative-mechanisms-of-action-in-pre-ctad-conference-webinar-300369786.html


'/>"/>
SOURCE Accera, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Heart Rhythm 2016: BIOTRONIK Provides a Forum for Physicians to Discuss the Importance of Extending Care Beyond the Implant
2. Fidson Healthcare Plc and GB Pharma Holdings position pharmaceutical outreach into Nigeria and Beyond!
3. Higher Breast Cancer Rates Will Push Treatment Market Beyond $17 Billion by 2021, says GBI Research
4. Beyond Philidor: Could Valeants New Pharmacy Arrangement Heighten Scrutiny From Lawmakers?
5. Pharma Sales to Grow Beyond $1 Trillion
6. Sysmex Moves Beyond a Better Box
7. From Illicit To Legal And Beyond To Pharmaceuticals - Global Markets, Competitors And Opportunities: Analysis And Forecasts 2015-2020
8. Beyond The Wrinkles: Botulinum Toxin A and Its Innovative Treatment for Bladder Disorders
9. Kalorama: EMR Market Expected To Grow Beyond Incentives
10. Kalorama: Beyond Brazil, Latin American IVD Market Grows
11. Two New Solutions From DePuy Synthes Companies Go Beyond The Implant For Orthopaedic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Global ... drainage devices are tubes used to remove excess liquid ... blood, serum, pus, urine, bile or lymph. Surgical drains ... of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, ... is prophylactic post-surgery to prevent accumulation of fluid e.g. ...
(Date:4/19/2017)... , April 19, 2017 The ... Application, Forecast to 2022 report has covered and analysed the ... and information on market size, shares and growth factors. The ... drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, 6 ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the Year, ... providing information destruction , recycling, and compliance services to businesses throughout ...
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
(Date:4/21/2017)... Maine (PRWEB) , ... April 21, 2017 , ... ... today announced it’s been named Agency of Record (AOR) for Theravent, Inc. ... or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... an exciting new partnership with the highly regarded and well renowned Asian distributor, ... innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen ...
Breaking Medicine News(10 mins):